Seres Therapeutics returns to Q2 FY26 net income of 4.58 million; revenue rises to 736,000

Reuters2026/08/05 11:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Seres Therapeutics swung to net income of USD 4.6 million in Q2 2026 from a loss a year earlier, driven by a USD 25 million VOWST sale gain.
Research and development expense fell 29.36% to USD 9.1 million; general and administrative expense dropped 31.46% to USD 7.1 million.
Operating loss narrowed to USD 21.3 million from USD 24.9 million; revenue was USD 736,000, versus no revenue a year earlier.
Cash and cash equivalents totaled USD 15.6 million at June 30; runway forecast through Q1 2027 including Nestlé milestone termination payments.
SER-155 irEC investigator-sponsored trial showed 80% immunosuppressive-free clinical response at day 15; Seres weighed partnering while cutting facility costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050700PRIMZONEFULLFEED9803909) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Seres Therapeutics returns to Q2 FY26 net income of 4.58 million; revenue rises to 736,000

You may also like

Crypto prices